\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Assessment of Time Gap between Repeated Re-Happening OIs among PLWHA who are Initiated ART between 2008 and 2013},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2014-01-15 (revised: 15 January 2014)}
\def\TheID{\makeatother }
\def\TheDate{2014-01-15}
\title{Assessment of Time Gap between Repeated Re-Happening OIs among PLWHA who are Initiated ART between 2008 and 2013}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Habtamu Mellie  Bizuayeyu}

             \affil[1]{  Debre Markos}

\renewcommand\Authands{ and }

\date{\small \em Received: 16 December 2013 Accepted: 31 December 2013 Published: 15 January 2014}

\maketitle


\begin{abstract}
        


Introduction: According to 2011 Ethiopian demographic health surveys the national and Amhara Region adult HIV prevalence was 1.5 % and 2.2% respectively. The major causes of morbidity and mortality of PLWHA (people living with HIV/AIDS) patients are OIs (opportunistic infections) that would occur in up to 40% of PLWHA. OIs are repeatedly happening in HIV (Human Immunodeficiency Virus) infected patients though there is no prior local evidence on time gap of repetition. Therefore the current study is aimed to determine time gap between repeated re-happening OIs and its associated factors among PLWHA who are initiated ART (Anti-Retroviral Treatment) Method: Institution based retrospective cohort study was conducted among 364 systematically selected PLWHA commencing ART. Time-gap was estimated using Kaplan-meier survival and actuarial life table. Hazard rate was calculated using Cox proportional-hazard model.Result: during follow up OIs were re-diagnosed in about three quarter (76.9%) of participants. In each week the probability of getting the re-happened OI was 1.1 per 100 persons. The median duration of staying free of OI re-happening was 66 weeks. In multivariate logistic regression, educational status, marital status, Prophylaxisis exposure, ART and Prophylaxisis drug adherence, hemoglobin and CD4 level were significantly associated with time gap of relapse.

\end{abstract}


\keywords{HIV/AIDS, survival, ART, PLWHA, ethiopia.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
lobally about 34 million people were living with HIV in 2012 \hyperref[b0]{1,}\hyperref[b1]{2} . Still, there were about 2.2 million new infections \hyperref[b2]{3} . Since the beginning of the epidemic nearly 30 million people have died of AIDSrelated causes \hyperref[b0]{1,}\hyperref[b1]{2,}\hyperref[b3]{4} .\par
At end of 2010 about 22.9 million which is 67\% of those living with HIV/AIDS globally are in Africa though only about 12\% of the world's population lives in the region \hyperref[b1]{2} . In terms of mortality, the region represents about 79\% of AIDS mortality globally \hyperref[b4]{5} , the estimated mortality from AIDS related illnesses at end of 2010 are 1.2 million 2 .\par
Author: Debre Markos University, College of medicine and health science, public health department. e-mail: habtamumellie@yahoo.com According to 2011 Ethiopian demographic health survey HIV prevalence in Ethiopia was 1.5 \% and in the study area of Amhara region, it was 2.2\% \hyperref[b5]{6} .\par
In Ethiopia the fee based and universal free access Antiretroviral (ARV) treatment was started in 2002/3 and 2004/5 respectively. The country uses decentralizing the ARV treatment service provision to the level of Health centers and private Health facilities for fast expansion of the service \hyperref[b6]{7} .\par
The major causes of morbidity and mortality of HIV/AIDS patients are OIs 8 that would occur in up to 40\% of PLWHA with a CD4 count less than 250/mm3 \hyperref[b8]{9} .\par
In North India, TB was the commonest OI (71\%) followed by candidiasis (39.3\%), PCP (7.4\%), cryptococcal meningitis and cerebral toxoplasmosis (3.7\% each) \hyperref[b9]{10} .\par
A national study in Ethiopia showed HIV patients' had OIs like Herpes Zoster scar (19.3\%); pulmonary tuberculosis (5.2\%) and pneumonia (5.2\%) and some patients (2\%) had more than one neurologic complications of HIV/AIDS \hyperref[b10]{11} . In Northwest Ethiopia about 7.5\% and8.3\% of the HIV patients' had pulmonary tuberculosis and Cryptococcal meningitis respectively  {\ref 12,} {\ref 13} . Nearly a quarter (22.7\%) of HIV patients' had chronic diarrhea in Southern Ethiopia 14 .\par
Even though, OIs are prevalent in the study area there is no local evidence on time gap between repeated re-happening OIs after prior treatment among PLWHA who are initiated ART. Thus the current study would give OI free time and its associated factors that can be used to plan resources and to identify PLWHA who need especial care. The evidence is expected to be used by governmental and non-governmental organizations working on HIV/AIDS. In the town there is one referral hospital and one health center that provide chronic HIV care. All 18 years old and above PLWHA who develop OI after 30 days of starting ART (the first 30 days after HAART were excluded due to most immune reconstitution inflammatory syndrome occurring in the period \hyperref[b11]{15} ) and taking standard treatment according to the Ethiopian Ministry of Health guideline were the study populations. HIV patients who take treatment for OI but not returned at least once to health institution for follow up; those who did not develop any OI since registered on HIV care after starting ART; and their follow up format incompletely documented when treatment for OI given or on consecutive follow ups were excluded from the study. 
\section[{II.}]{II.} 
\section[{Methods and Materials}]{Methods and Materials} 
\section[{b) Sampling and data collection procedure}]{b) Sampling and data collection procedure}\par
The sample size was calculated based on the assumption of 95\% confidence interval and 2.5\% of absolute precision and the proportion of pulmonary tuberculosis (6\%) among PLWHA who are initiating ART \hyperref[b12]{16} . The calculate sample size using Open Epi Version 2.3, May 2009 was 347 and after adding 5\% contingency the final sample size was becoming 364.\par
After preparing the sampling frame among PLWHA commencing ART that fulfill the inclusion criteria, selection of study participants were done using simple random sampling technique via random number table method.\par
Data collection instrument was developed from both federal ministry of health chronic HIV care form and the patient's card in which the follow up health status data were registered. Then the needed data was collected by reviewing ART follow up form, laboratory request and patients' card. If laboratory examinations like CD4 count, Hemoglobin, weight are not found during entry and exit to the study, the measurements that are most nearest to time of entry and exit to study were taken as baseline and end line predictors respectively.\par
Participants whose future time re-happening of OI not confirmed due to loss follow-up/dropout/transferred out/dead by any disease other than OI/cause of death not confirmed during study period or not develop OI at end of the study period were censored.\par
Health professionals working on ART clinics were collecting the data after taking appropriate training on objective of the study and about the data collection instrument in detail. iii. Censored: None re-happening of OI in study participant during follow up on study; but future re-happening is not certain. iv. Drop out: if PLWHA on HIV care lost to follow-up above 3 months as recorded by health personnel working on ART clinic.\par
v. Lost to follow-up: if PLWHA on HIV care not seen for >1 month as recorded by health personnel working on ART clinic. vi. Transferred-out: if PLWHA on HIV care in one health institution shift to other health institution.\par
vii. Good Adherence: if PLWHA adherent > 95 \% that is the percentage of missed dose is < 2 doses of 30 doses or <3 dose of 60 dose) as documented by health personnel working on ART clinic.\par
viii. Fair Adherence: if PLWHA adherent 85-94 \% that is the percentage of missed dose is 3-5 doses of 30 doses or 3-9 dose of 60 dose) as documented by health personnel working on ART clinic.\par
ix. Poor Adherence: if PLHIV adherent <85\% that is the percentage of missed dose is > 6 doses of 30 doses or >9 dose of 60 dose) as documented by health personnel working on ART clinic. 
\section[{d) Statistical Analysis}]{d) Statistical Analysis}\par
A coded questionnaire was double entered in to Epi Info version 3.5.1 statistical package by a trained data clerk and exported to SPSS version 20 and STATA version11 statistical packages for analysis of statistical inferences. Before further analysis, data cleaning was done using frequencies, cross tabulations, sorting and listing to check missed values and outliers. Errors identified during the process were corrected by revising the original questionnaire.\par
To estimate the time of OI free duration, the actuarial life table and Kaplan Meier survival was used. Assumption of proportional-hazard was checked using Schoenfeld residual with p-value >0.1(?=10\%) and the assumption was not violated. Base line and end line hemoglobin value was correlated (r=0.48, p=0.006) thus end line hemoglobin value was excluded from multivariate analysis due to affecting the final model by its redundancy nature which affects precision of estimate. The hazard rate at uni-variate and Multivariate level was calculated using Cox proportional-hazard model. Variables having p-value <0.05 at uni-variate analysis and not collinear was entered into final model of multivariate analysis to identify associated factors with outcome. clinics prepared the sampling frame and extracted the data from medical records. In addition no personal identifier was extracted on medical records. 
\section[{III.}]{III.} 
\section[{Result}]{Result}\par
In the six year follow up period majority of the participants were females (64.6\%), orthodox Christians (91.6\%), living in urban (74.5\%), married (46.4\%), not educated (41.5\%) and not employed (74.2\%) in governmental or private sectors. Their median age was 32 years in which all most all of them were below 50 years old (table \hyperref[tab_0]{1}).\par
The base line and end line CD4 count values were 159 and 313 cells/ul respectively. The respective base line and end line mean values for hemoglobin were 11.9 (±2.5) and 12.4 (±1.9) g/dl and for body mass index it was 18.9 (±3) and 19.7 (±2.9) kg/m 2 . At start of the study about 72\% of the participants were diagnosed only one type of OI while the rest was diagnosed 2 or more OIs at one visit of health institution. Of the diagnosed OIs at start about half (51.1\%) was having WHO stage III OI. All most all (98.4\%) the participants have no other concomitant chronic diseases like hypertension, cardiac disease, and diabetes mellitus. Nearly all study subjects were having working functional status both at base line (71.7\%) and at follow up (89\%). All participants were on first line ART regimens in which about 40.4\% and 56.9\% were taking Tenofovirdisoproxilfumarate+ Lamivudine+Efavirenzregi men both at base line and at end line respectively and their drug adherence status was good both at base line (94.8\%) and at follow up (93.7\%). Most of the study subjects were taking Prophylaxis is both at base line (93.1\%) and at follow up (92.3\%) and their drug adherence status was good both at base line (95.7\%) and at follow up (94.5\%) (Table1). 
\section[{a) Time gap of OI re-happening and associated factors}]{a) Time gap of OI re-happening and associated factors}\par
During follow up the cumulative incidence of OI re-happening was 76.9\% (95\% CI: 72.6-81.25) and the incidence rate was 1.1 (95\% CI: 0.97-1.23) per 100 person weeks. The commonly re-happening OIs were recurrent upper respiratory tract infection (19.3\%), bacterial pneumonia (12.1\%), oral candidiasis (10.4\%), chronic diarrhea (9.3\%), herpes zoster (9.3\%), pulmonary tuberculosis (6.1\%), extra pulmonary tuberculosis (7.1\%), PCP (3.9\%), encephalopathy (3.9\%), toxoplasmosis (3.2\%), and other types (3.3\%).\par
According to Kaplan Meier survival estimation, the median time of OI re-happening was 66 (95\% CI: 57.87-74.13) weeks (figure 1). As the actuarial life table analysis showed the probability of free of OI rehappening with in the first five weeks was 97\% and it was becoming <10\% and <1\% after 180 and 255 weeks respectively.\par
After adjustment for potential confounders in multivariate cox proportional hazard model, the factors that delay re-happening of OIs were being educated than non-educated, taking Prophylaxisis at follow up, having a hemoglobin level above 10 g/dl at base line, having a CD4 level above 100 compared <100 cells/ul both at base line and at end line. But being widowed compared to married and not adhering ART drug at base line were risks for short time re-happening of OIs (Table \hyperref[tab_0]{1}). IV. 
\section[{Discussion}]{Discussion}\par
In current study, the cumulative incidence of OI re-happening was 76.9\% and the commonly rehappening OIs were recurrent upper respiratory tract infection (19.3\%), bacterial pneumonia (12.1\%), oral candidiasis (10.4\%), chronic diarrhea (9.3\%), and herpes zoster (9.3\%). And this finding was nearly in agreement with prior studies \hyperref[b8]{9,}\hyperref[b9]{10,} {\ref [12]} {\ref [13]} {\ref [14]}\hyperref[b12]{16} though some figures are slightly vary among prior findings each other and with the current study due to difference in study design (prior ones are cross sectionals), and study area which is conducted in various socio-economic characteristics.\par
With regarding sex various studies having contradicting outcome as risk for OI. In a cohort study, female sex increases the risk of toxoplasmic encephalitis \hyperref[b13]{17} . A cohort study in United states showed female gender, were associated with significantly higher odds of OIs like herpes simplex virus-2 infection \hyperref[b14]{18} . In contrary, a study in Thailand and showed male gender was significantly associated with higher incidence of OIs after ART \hyperref[b15]{19} . In current study sex is not significantly associated and the possible reasons might be vary in study population, study design and differences in sociocultural contexts of the source population.\par
One of the factor that delay OI re-happening in current study was having a CD4 count above 100 compared <100 cells/ul both at base line and at end line and this finding was in conformity with other studies \hyperref[b13]{17,} {\ref [20]}\hyperref[b17]{[21]} {\ref [22]} {\ref [23]} . The HIV cohort study in Switzerland showed the baseline CD4 count is one of the predictor for OI progression  {\ref 20} . Another cohort study also showed higher CD4 cell count was associated with a reduction of risk of new OI progression  {\ref 23} .\par
The current finding shown as exposure for prophylaxis at follow up would delay repeated rehappening of OIs and this is in supported by other studies \hyperref[b17]{21,}\hyperref[b19]{[24]}\hyperref[b20]{[25]}\hyperref[b21]{[26]}\hyperref[b22]{[27]} . Primary prophylaxis with Trimethoprimsulfamethoxazole is preventing OIs \hyperref[b19]{24} . Cotrimoxazole prophylaxis prevents diarrhea among PLWHA after ART initiation \hyperref[b21]{26} .\par
In current study not adhering ART drug at base line was the risk for short time re-happening of OIs and the result was supported by two studies  {\ref 12,}\hyperref[b23]{28} in which non-adherence of ART was the risk of failure the drug which enhances OI spread. 
\section[{V. Conclusion and Recommendation}]{V. Conclusion and Recommendation}\par
OIs were re-diagnosed in majority of participants. In each week the probability of getting the re-happened OI was 1.1 per 100 persons. The median duration of staying free of OI re-happening was 66 weeks. Participants who were educated, taking Prophylaxisis, having a hemoglobin level above 10 g/dl, having a CD4 level above 100 compared <100 cells/ul would not visit heath institutions due to re-happened OI illness on short periods. Whereas those who were widows compared to married and not adhering ART drug would visit heath institutions due to re-happened OI illness on short periods.  
\section[{VI. Acknowledgment}]{VI. Acknowledgment}\par
First of all, my deepest gratitude goes to Professor Getnet Mitkie, Dr Alemayehu Worku and Dr Fikre Enquselassie for their continuous and unreserved supports on completion of the work. In addition I would like to thank data collectors and supervisors and the managers of health institutions for giving permission to conduct the study.\begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{fig_0}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-3.png}
\caption{\label{fig_1}}\end{figure}
   \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.19895461499235081\textwidth}P{0.12353391126976032\textwidth}P{0.12960224375318716\textwidth}P{0.03771035186129525\textwidth}P{0.1785823559408465\textwidth}P{0.18161652218255991\textwidth}}
Variables\tabcellsep \multicolumn{2}{l}{Diagnosis of Re-happening}\tabcellsep Median\tabcellsep CHR (95\% CI)\tabcellsep AHR (95\% CI)\\
\tabcellsep OI\tabcellsep \tabcellsep KMS\tabcellsep \tabcellsep \\
\tabcellsep No (\%)\tabcellsep Yes (\%)\tabcellsep \tabcellsep \tabcellsep \\
Marital status\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Married\tabcellsep 45(53.6)\tabcellsep 124 (44.3)\tabcellsep 73\tabcellsep 1\tabcellsep 1\\
Single\tabcellsep 13(15.5)\tabcellsep 48(17.1)\tabcellsep 79\tabcellsep 1.15(0.82-1.60)\tabcellsep 0.71(0.42-1.21)\\
Divorced\tabcellsep 18(21.4)\tabcellsep 76(27.1)\tabcellsep 72\tabcellsep 1.11(0.83-1.49)\tabcellsep 0.81(0.52-1.27)\\
Widowed\tabcellsep 8(9.5)\tabcellsep 32(11.4)\tabcellsep 35\tabcellsep 2.12(1.43-3.14)\tabcellsep 4.65(2.13-10.16)\\
Educational status\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Not educated\tabcellsep 21(25)\tabcellsep 130(46.4)\tabcellsep 61\tabcellsep 1\tabcellsep 1\\
Grade 1-8\tabcellsep 19(22.6)\tabcellsep 82(29.3)\tabcellsep 54\tabcellsep 0.76(0.57-1.0)\tabcellsep 0.78(0.47-1.28)\\
Grade 9-12\tabcellsep 21(25)\tabcellsep 53(18.9)\tabcellsep 75\tabcellsep 0.62(0.45-0.87)\tabcellsep 0.25(0.13-0.48)\\
Above grade 12\tabcellsep 23(27.4)\tabcellsep 15(5.4)\tabcellsep 170\tabcellsep 0.38(0.22-0.64)\tabcellsep 0.14(0.05-0.43)\\
Occupational status\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Un-employed\tabcellsep 47(56)\tabcellsep 223(79.6)\tabcellsep 56\tabcellsep 1\tabcellsep 1\\
Employed\tabcellsep 37(44)\tabcellsep 57(20.4)\tabcellsep 92\tabcellsep 0.61(0.46-0.82)\tabcellsep 0.85(0.51-1.41)\\
WHO staging B.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
I\tabcellsep 3(3.6)\tabcellsep 22(7.9)\tabcellsep 72\tabcellsep 1\tabcellsep 1\\
II\tabcellsep 30(35.7)\tabcellsep 77(27.5)\tabcellsep 85\tabcellsep 0.49(0.31-0.79)\tabcellsep 0.80(0.35-1.80)\\
III\tabcellsep 42(50)\tabcellsep 144(51.4)\tabcellsep 61\tabcellsep 0.53(0.33-0.83)\tabcellsep 0.52(0.23-1.16)\\
IV\tabcellsep 9(10.7)\tabcellsep 37(13.2)\tabcellsep 47\tabcellsep 0.61(0.36-1.04)\tabcellsep 0.32(0.098-1.01)\\
Prophylaxisis\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
exposure B.\tabcellsep 4(4.8)\tabcellsep 21(7.5)\tabcellsep 33\tabcellsep 1\tabcellsep 1\\
No\tabcellsep 80(95.2)\tabcellsep 259(92.5)\tabcellsep 72\tabcellsep 0.48(0.31-0.75)\tabcellsep 0.24(0.08-0.69)\\
Yes\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Prophylaxisis\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
exposure F.\tabcellsep 5(6)\tabcellsep 23(8.2)\tabcellsep 21\tabcellsep 1\tabcellsep 1\\
No\tabcellsep 79(94)\tabcellsep 257(91.8)\tabcellsep 69\tabcellsep 0.61(0.40-0.94)\tabcellsep 0.41(0.16-1.03)\\
Yes\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Prophylaxisis\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
adherence B.\tabcellsep 84(100)\tabcellsep 247(94.3)\tabcellsep 72\tabcellsep 1\tabcellsep 1\\
Good\tabcellsep 0(0)\tabcellsep 6(2.3)\tabcellsep 67\tabcellsep 1.0(0.45-2.26)\tabcellsep 0.21(0.05-1.0)\\
Fair\tabcellsep 0(0)\tabcellsep 9(3.4)\tabcellsep 35\tabcellsep 3.37(1.71-6.64)\tabcellsep 3.62(0.32-41)\\
Poor\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Prophylaxisis\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
adherence F .\tabcellsep 82(97.6)\tabcellsep 244(93.5)\tabcellsep 72\tabcellsep 1\tabcellsep 1\\
Good\tabcellsep 2(2.4)\tabcellsep 6(2.3)\tabcellsep 45\tabcellsep 2.30(1.01-5.23)\tabcellsep 3.44(0.91-12.97)\\
Fair\tabcellsep 0(0)\tabcellsep 11(4.2)\tabcellsep 35\tabcellsep 3.42(1.85-6.32)\tabcellsep 4.48(0.98-20.50)\\
Poor\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
ART adherence B.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Good\tabcellsep 80(95.2)\tabcellsep 265(94.6)\tabcellsep 71\tabcellsep 1\tabcellsep 1\\
Fair\tabcellsep 4(4.8)\tabcellsep 7(2.5)\tabcellsep 42\tabcellsep 1.71(0.81-3.64)\tabcellsep 15.35(3.12-75.55)\\
Poor\tabcellsep 0(0)\tabcellsep 8(2.9)\tabcellsep 24\tabcellsep 4.18(2.05-8.53)\tabcellsep 4.21(0.39-45.83)\\
ART adherence F.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
Good\tabcellsep 83(98.8)\tabcellsep 258(92.1)\tabcellsep 72\tabcellsep 1\tabcellsep 1\\
Fair\tabcellsep 1(1.2)\tabcellsep 9(3.2)\tabcellsep 41\tabcellsep 2.32(1.19-4.53)\tabcellsep 0.97(0.34-2.65)\\
Poor\tabcellsep 0(0)\tabcellsep 13(4.6)\tabcellsep 24\tabcellsep 3.69(2.1-6.50)\tabcellsep 1.04(0.16-6.80)\\
CD4 count (cells/?l) B.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
<=100\tabcellsep 9(10.7)\tabcellsep 23(8.2)\tabcellsep 66\tabcellsep 1\tabcellsep 1\\
101-199\tabcellsep 19(22.6)\tabcellsep 49(17.5)\tabcellsep 75\tabcellsep 0.60(0.36-0.99)\tabcellsep 0.29(0.12-0.71)\\
200-350\tabcellsep 25(29.8)\tabcellsep 98(35)\tabcellsep 61\tabcellsep 0.76(0.48-1.20)\tabcellsep 0.60(0.26-1.38)\\
351-499\tabcellsep 18(21.4)\tabcellsep 70(25)\tabcellsep 50\tabcellsep 0.69(0.43-1.12)\tabcellsep 1.30(0.52-3.24)\\
>=500\tabcellsep 13(15.5)\tabcellsep 40(14.3)\tabcellsep 123\tabcellsep 0.33(0.19-0.56)\tabcellsep 0.87(0.34-2.26)\\
CD4 count (cells/?l) F.\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
<=100\tabcellsep 4(10.3)\tabcellsep 14(7.4)\tabcellsep 45\tabcellsep 1\tabcellsep 1\\
101-199\tabcellsep 6(15.4)\tabcellsep 26(13.8)\tabcellsep 75\tabcellsep 0.57(0.29-1.09)\tabcellsep 1.19(0.45-3.15)\\
200-350\tabcellsep 12(30.8)\tabcellsep 68(36.2)\tabcellsep 83\tabcellsep 0.50(0.28-0.90)\tabcellsep 0.87(0.36-2.10)\end{longtable} \par
 
\caption{\label{tab_0}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.7745967741935483\textwidth}P{0.07540322580645162\textwidth}}
?\tabcellsep \\
\tabcellsep Year 2014\\
Based on this study finding, the following recommendations can be forwarded ? Key, B.=base line value F.=follow up value CI=confidence interval KMS=Kaplan Meier survival in weeks CHR=crude hazard rate AHR=Adjusted hazard rate\tabcellsep ( D D D D ) K\end{longtable} \par
 
\caption{\label{tab_1}}\end{figure}
 			\footnote{© 2014 Global Journals Inc. (US)} 		 		\backmatter  			 			 			  				\begin{bibitemlist}{1}
\bibitem[ UNAIDS World AIDS Day report ()]{b3}\label{b3} 	 		\textit{},  	 	 		\textit{UNAIDS World AIDS Day report}  		2012.  	 	 (Regional Fact Sheet) 
\bibitem[Wafaa et al. (1999)]{b22}\label{b22} 	 		‘A Randomized Trial of Daily and Thrice-Weekly Trimethoprim-Sulfamethoxazole for the Prevention of Pneumocystis carinii Pneumonia in Human Immunodeficiency Virus-Infected Persons’.  		 			M E Wafaa 		,  		 			M Y Teresa 		,  		 			L Roberta 		.  	 	 		\textit{Clinica Infectious Disease}  		29 October 1999. 29 p. .  	 
\bibitem[Surendrak et al. (2010)]{b11}\label{b11} 	 		‘a study of TB associated immune reconstitution inflammatory syndrome using the consensus case definition’.  		 			Surendrak 		,  		 			Sharma 		,  		 			Sahajaldhooria 		,  		 			Paragbarwad 		.  	 	 		\textit{Indian J Med Res}  		June 2010. 131 p. .  	 
\bibitem[Edward et al. ()]{b4}\label{b4} 	 		‘Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America: A Meta-analysis’.  		 			J Edward 		,  		 			J Mills 		,  		 			B Iain 		.  	 	 		\textit{JAMA}  		2006. 296  (6)  p. .  	 
\bibitem[V'eroniqueerard ()]{b16}\label{b16} 	 		‘AIDS-related opportunistic illness occurring after initiation of potent antiretroviral therapy, the Swiss HIV cohort study’.  		 			V'eroniqueerard 		.  	 	 		\textit{JAMA December}  		1999. 15  (23)  p. .  	 
\bibitem[Annual Performance Report of Multi-sectoral HIV/ AIDS Response, Federal HIV/AIDS Prevention and Control Office ()]{b6}\label{b6} 	 		\textit{Annual Performance Report of Multi-sectoral HIV/ AIDS Response, Federal HIV/AIDS Prevention and Control Office},  		2002. 2009/2010.  	 
\bibitem[Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV/AIDS -Research and Palliative Care ()]{b19}\label{b19} 	 		\textit{Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV/AIDS -Research and Palliative Care},  		2011. 319 p. 33.  	 
\bibitem[Antinori et al. ()]{b13}\label{b13} 	 		‘Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy’.  		 			Andrea Antinori 		,  		 			Dora Antonellacingolani 		,  		 			Larussa 		.  	 	 		\textit{Clinical Infectious Diseases}  		2004. 39 p. .  	 
\bibitem[Jaaw ()]{b20}\label{b20} 	 		‘Clinical Evidence HIV: primary and secondary prophylaxis for opportunistic infections’.  		 			Powderly Jaaw 		.  	 	 		\textit{Clinical Evidence}  		2010. 06 p. 908.  	 
\bibitem[Ethiopia Demographic and Health Survey Central Statistical Agency (CSA) (2011)]{b5}\label{b5} 	 		‘Ethiopia Demographic and Health Survey’.  	 	 		\textit{Central Statistical Agency (CSA)},  				 (Addis Ababa Ethiopia, ICF International Calverton, Maryland, USA)  		2011. March 2012.  	 	 (final draft report) 
\bibitem[Kumarasamy and Devaleenol ()]{b12}\label{b12} 	 		‘Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India’.  		 			N Kumarasamy 		,  		 			Bella Devaleenol 		.  	 	 		\textit{Journal of Infectious Diseases}  		2010. 14 p. .  	 
\bibitem[
			US
		 (2011)]{b0}\label{b0} 	 		\textit{GLOBAL HEALTH POLICY FACT SHEET, the Global HIV/AIDS Epidemic},  		 			US 		.  		November 2011.  	 
\bibitem[GLOBAL HIV/AIDS RESPONSE -Epidemic update and health sector progress towards Universal Access ()]{b1}\label{b1} 	 		\textit{GLOBAL HIV/AIDS RESPONSE -Epidemic update and health sector progress towards Universal Access},  		2011.  	 	 (-Progress Report) 
\bibitem[James et al. ()]{b21}\label{b21} 	 		‘HIV-Infected Ugandan Adults Taking Antiretroviral Therapy With CD4 Counts .200 Cells/lL Who Discontinue Cotrimoxazole Prophylaxis Have Increased Risk of Malaria and Diarrhea’.  		 			D James 		,  		 			D Campbell 		,  		 			D Richard 		.  	 	 		\textit{Clinical Infectious Diseases}  		2012. 54  (8)  p. .  	 
\bibitem[Manosuthi et al. (2007)]{b15}\label{b15} 	 		‘Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting’.  		 			W Manosuthi 		,  		 			A Chaovavanich 		,  		 			S Tansuphaswadikul 		.  	 	 		\textit{Epub}  		2007 Nov. Matthias Erard. 55  (5)  p. .  	 
\bibitem[Joint United Nations Programme on HIV/AIDS ()]{b2}\label{b2} 	 		\textit{Joint United Nations Programme on HIV/AIDS},  		2012. Geneva.  	 	 (Together we will end AIDS) 
\bibitem[Longitudinal Cohort Study from COHERE PLoS Medicine (2012)]{b18}\label{b18} 	 		‘Longitudinal Cohort Study from COHERE’.  	 	 		\textit{PLoS Medicine}  		March 2012. 9  (3)  p. e1001194.  	 
\bibitem[Abebe and Mzhwnnn (2008)]{b7}\label{b7} 	 		\textit{Opportunistic and other intestinal parasitic infections in AIDS patients, HIV seropositive healthy carriers and HIV seronegative individuals in southwest Ethiopia},  		 			G Abebe 		,  		 			Mzhwnnn 		.  		Dec 2008. 5 p. .  	 
\bibitem[Sow et al. (2012)]{b23}\label{b23} 	 		‘Predictors of ART adherence among HIV infected individuals in Dakar’.  		 			P G Sow 		,  		 			Ktmc 		,  		 			A T Dia 		,  		 			I Traore 		.  	 	 		\textit{Senegal. Journal of Medicine and Medical Science}  		April 2012. 3  (4)  p. .  	 
\bibitem[Patel et al. (2012)]{b14}\label{b14} 	 		‘Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States’.  		 			P Patel 		,  		 			T Bush 		,  		 			K H Mayer 		.  	 	 		\textit{Sex Transm Dis}  		2012 Feb. 39  (2)  p. .  	 
\bibitem[Gallant and Chaisson ()]{b8}\label{b8} 	 		‘Prophylaxis for opportunistic infections in patients with HIV infection’.  		 			J M Gallant 		,  		 			R Chaisson 		.  	 	 		\textit{Ann Intern Med}  		1994. 120 p. .  	 
\bibitem[Tesfayeberhe and Amanuelamare ()]{b10}\label{b10} 	 		‘ShimelisAssefa, BerhanuErko, GirmayMedhin, ZelalemAssefa and TechalewShimelis. Intestinal parasitic infections in relation to HIV/AIDS status, diarrhea and CD4 T-cell count’.  		 			Yilmamelkamuand Tesfayeberhe 		,  		 			Amanuelamare 		.  	 	 		\textit{BMC Infectious Diseases}  		2010 Jul. 2009. 48  (3)  p. 155.  	 	 (Ethiop Med J.) 
\bibitem[Sk Sharma and Tamilarasukadhiravan (2004)]{b9}\label{b9} 	 		‘Spectrum of clinical disease in a series of 135 hospitalized HIV-infected patients from north India’.  		 			Sk Sharma 		,  		 			Tamilarasukadhiravan 		.  	 	 		\textit{BMC Infectious Diseases}  		22 November 2004. 4 p. 52.  	 
\bibitem[Losina et al. ()]{b17}\label{b17} 	 		‘The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV infected Adults in Côte d'Ivoire France’.  		 			Elena Losina 		,  		 			Sylvie Yazdanyazdanpanah 		,  		 			Deuffic-Burban 		.  	 	 		\textit{AntivirTher}  		2007. 12  (4)  p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
